Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Merck
Colorcon
Baxter

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Shire LLC, Supernus Pharmaceuticals, Incl v. IMPAX Laboratories, Inc. (N.D. Cal. 2010)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Shire LLC, Supernus Pharmaceuticals, Incl v. IMPAX Laboratories, Inc. (N.D. Cal. 2010)

Docket   Start Trial Date Filed 2010-12-02
Court District Court, N.D. California Date Terminated 2013-06-19
Cause 35:145 Patent Infringement Assigned To Richard G. Seeborg
Jury Demand None Referred To Maria-Elena James
Parties ANDA, INC; IMPAX LABORATORIES, INC.; M.D. PASKO RAKIC; M.D. ROBERT D. HUNT; PH.D AMY F.T, ARNSTEN; SHIRE LLC, SUPERNUS PHARMACEUTICALS, INC; WATSON LABORATORIES, INC.-FLORIDA; WATSON PHARMA, INC.; WATSON PHARMACEUTICALS, INC.
Patents 5,854,290; 6,287,599; 6,303,607; 6,811,794
Attorneys Benjamin A. Katzenellenbogen; Colin Barry Heideman; Erika V. Selli; Heather Morehouse Ettinger; Jeffrey James Toney; John Lincoln North; Jonathan David Olinger; Joseph R. Robinson; Joseph V. Saphia; Laura Fahey Fritts; Matthew Daniel Murphey; Norman E.B. Minnear; Sarika Singh; Scott Robert Raber; Sheila Neha Swaroop; William G. Gaede , III; William Rolland Zimmerman
Firms Kasowitz Benson Torres and Friedman; Kasowitz, Benson, Torres & Friedman LLP; Knobbe Martens Olson & Bear LLP; Knobbe Martens Olson and Bear; McDermott Will & Emery LLP; McDermott Will and Emery LLP; Troutman Sanders LLP; Troutman Sanders LLP, the Chrysler Building; Wiggin and Dana LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Shire LLC, Supernus Pharmaceuticals, Incl v. IMPAX Laboratories, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Shire LLC, Supernus Pharmaceuticals, Incl v. IMPAX Laboratories, Inc. (N.D. Cal. 2010)

Date Filed Document No. Description Snippet Link To Document
2012-02-21 143 Exhibit F - Impax Claim Construction Proposals 2606); U.S. Patent No. 6,303,607, Table 4, Examples 1, 2A-2C (IMPXGNF0002799… (IMPAXGNF0002935-2958); U.S. Patent No. 6,303,607, Abstract, col. 2, ll. 45-52, col. 4, ll… 2606); U.S. Patent No. 6,303,607, Table 4, Examples 1, 2A-2C (IMPXGNF0002799… (IMPAXGNF0002935-958); U.S. Patent No. 6,303,607, Abstract, col. 2, ll. 45-52, col. 4, ll… ’290 Patent Claim 4 4. The method of claim 1, wherein the primate is a human. ’290 Patent Claim External link to document
2012-04-20 154 . The Patents-in-Suit 12 The patents-in-suit are U.S. Patent No. 6,287,599 (“the ‘599 patent… patent”) and U.S. Patent No. 13 6,881,794 (“the ‘794 patent”).4 The inventions claimed in these patents… 2. The ‘794 Patent 2 Similar to the ‘599 patent, the ‘794 patent relates to sustained…in any patent case, because it is the first step 19 in both the patent infringement and patent invalidity… interpreting the patents’ data, and adding clarity where possible. The 7 patents’ disclosures are External link to document
2012-04-20 155 Exhibit Pls. Opening Claim Construction Brief 2012 03 22 Mem Opinion, # 4 Exhibit US Pat No. 6,287,599, # 5 Exhibit US Pat No. 6,811,794, # 6 Exhibit…2010 19 June 2013 3:10-cv-05467 830 Patent None District Court, N.D. California External link to document
2012-05-04 166 Table 2, column 5 of U.S. 6 Patent No. 6,287,599 (the "'599 patent") is headed “Guanfacine…of 18 1 OTHER AUTHORITIES 2 U.S. Patent No. 6,287,599 ........................................…invention, its 26 purpose, and the patent specification. The patents claim a pharmaceutical composition…the patents construed by the parties and Plaintiffs’ claim construction 26 because “[t]he patent is …because Tables 9 and 10 of U.S. Patent No. 6,811,794 (the "'794 patent") summarize 22 data External link to document
2012-06-01 180 collectively “Shire”) allege infringement of U.S. Patent Nos. 6,287,599 (“the ’599 … A third patent, U.S. Patent No. 5,854,290 (“the ’290 patent”), was originally asserted… 20 patent”) and 6,811,794 (“the ’794 patent”).1 Shire holds an exclusive license… 13 a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to which the… 4 of the ’599 patent’s claims. Most prominently, in the ’599 patent’s first claim, it constitutes External link to document
2012-07-12 192 Summary Judgment of NonInfringement of U.S. Patent 5,854,290 filed by IMPAX Laboratories, Inc.. Motion …2010 19 June 2013 3:10-cv-05467 830 Patent None District Court, N.D. California External link to document
2012-07-13 193 Summary Judgment of NonInfringement of U.S. Patent 5,854,290 filed by IMPAX Laboratories, Inc. Motion Hearing…2010 19 June 2013 3:10-cv-05467 830 Patent None District Court, N.D. California External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
Baxter
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.